What is Thalomid?
Thalomid® is an oral cancer drug that was originally developed in the 1950s as a treatment for insomnia and morning sickness. Further research on Thalomid showed it to be highly active against myeloma. When the findings of that research were published in 1999, Thalomid was considered to be the first new agent with major activity against myeloma in more than 30 years.
Thalomid is part of a class of drugs called Immunomodulatory drugs or IMiDs®. IMiDs work against cancer cells partly by impacting the functioning of the immune system.